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Medical imaging technologies have undergone explosive growth over the past few
decades and now play a central role in clinical oncology. But the truly transformative
power of imaging in the clinical management of cancer patients lies ahead. Today,
imaging is at a crossroads, with molecularly targeted imaging agents expected to broadly
expand the capabilities of conventional anatomical imaging methods. Molecular imaging
will allow clinicians to not only see where a tumor is located in the body, but also to
visualize the expression and activity of specific molecules (e.g., proteases and protein
kinases) and biological processes (e.g., apoptosis, angiogenesis, and metastasis) that
influence tumor behavior and/or response to therapy. Breast cancer, the most common
cancer among women and a research area where our group is actively involved, is
a very heterogeneous disease with diverse patterns of development and response to
treatment. Hence, molecular imaging is expected to have a major impact on this type
of cancer, leading to important improvements in diagnosis, individualized treatment, and
drug development, as well as our understanding of how breast cancer arises.
Keywords: breast cancer, molecular imaging of breast, breast cancer diagnosis, contrast agents, breast imaging
techniques, breast magnetic resonance imaging
INTRODUCTION
Modern clinical cancer treatments require precise positional
information. Where is the tumor located? How large is it?
Is it confined, or has it spread to the lymph nodes? Does
it involve any critical anatomical structures that would alter
the treatment strategy? These questions are being answered, at
ever-increasing spatial resolution, through the application of
traditional anatomical imaging methods such as computed x-
ray tomography (CT), magnetic resonance imaging (MRI), and
ultrasound (US). Although these methods still represent the
mainstay of clinical imaging, it has become clear that the acqui-
sition of molecular and physiological information by nuclear
magnetic resonance and optical imaging technologies could vastly
enhance our ability to fight cancer (Weissleder, 2006).
Emerging genomic and proteomic technologies have the
potential to transform the way in which breast cancer is clini-
cally managed. Molecular imaging is poised to play a central role
in this transformation, because it will allow the integration of
molecular and physiological information specific to each patient
with anatomical information obtained by conventional imaging
methods. The hope is that clinical molecular imaging will one
day be used to achieve the following: (i) the early detection of
molecular or physiological alterations that signal the presence of
cancer when it is still at a curable stage, (ii) the ability to evaluate
and adjust treatment protocols in real time, and (iii) the ability to
streamline the cancer drug development process.
The development of new breast cancer therapeutics is expen-
sive, time-consuming, and often requires vast numbers of
patients. Molecular imaging is currently one of the most powerful
non-invasive techniques used in clinical diagnosis that exhibits a
high potential to improve the efficiency and cost-effectiveness of
drug development programs. In this article we present a short
review on the main techniques and the perspectives of future
Breast Cancer Imaging.
IMAGING TECHNIQUES FOR BREAST CANCER
Mammography and ultrasound are the most common methods
used for diagnosis and guided intervention in breast disease.
The relevance of breast MRI has been also increased, fulfiling an
important role in operated breasts and suspicious lesions.Multiple
diagnostic techniques, including tomosynthesis, mammography
and ultrasound contrast elastography, 3D ultrasound, diffusion
and perfusion and breast spectroscopy, have also been developed.
Moreover, the use of the American College of Radiology (ARC)
BIRADS scale (Breast Imaging Reporting and Data System) has
been implemented in diagnostic centers during the last decade
(American College of Radiology, 2003). BIRADS classification
started in the late 1980s to address a lack of standardization
and uniformity in mammography practice reporting (McLelland
et al., 1991). The BIRADS lexicon provided new opportunities
for quality assurance, communication, research, and improved
patient care. Many well-respected groups participated in this
development initiative to establish a broad base of support (D’orsi
and Kopans, 1997; Burnside et al., 2009; Mercado, 2014).
The BIRADS scale is a classification of breast disease accord-
ing to radiological findings that includes six grades of malignancy
and indicates the actions that must be followed for each grade
(Figure 1). The implementation of BIRADS has allowed us to
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FIGURE 1 | Microcalcifications in breast mammography. Highly
suggestive of malignancy BIRADS 5.
homogenize the diagnosis and injury treatment methods in all
centers.
BIRADS CLASSIFICATION
Category 0: Additional imaging evaluation and/or comparison
to prior mammograms is needed.
Category 1: Negative.
Category 2: Benign (non-cancerous) finding.
Category 3: Probably benign finding – Follow-up in a short time
frame is suggested.
Category 4: Suspicious abnormality – Biopsy should be consid-
ered:
Category 4A: Finding with a low suspicion of being
cancer.
Category 4B: Finding with an intermediate suspi-
cion of being cancer.
Category 4C: Finding of moderate concern of being
cancer, but not as high as Category 5.
Category 5: Highly suggestive of malignancy – Appropriate
action should be taken.
Category 6: Known biopsy-proven malignancy – Appropriate
action should be taken.
The main diagnosis and monitoring techniques of breast dis-
ease include mammography, ultrasound and magnetic resonance
imaging (MRI).
MAMMOGRAPHY
Mammography is the most commonly used method for the mon-
itoring and diagnosis of breast disease. In recent years, digital
mammography has been developed, which requires lower doses
of radiation as compared to a conventional mammography, and
also allows the post-processing of images.
Mammography is also used to guide interventional breast tech-
niques, such as stereotactic mammography. Two mammographic
views, cranio-caudal and oblique medium lateral are usually per-
formed and complemented with other projections according to
needs. This technique has high sensitivity for the diagnosis of
microcalcifications. It is also used for breast screening, allowing
the detection of breast lesions at a very early stage, which increases
considerably the life expectancy of affected patients. According
to the screening program, a mammography is usually performed
every two years (two projections) in women over the age of 40
or 50, with double read by two different radiologists (Houssami
et al., 2009).
However, mammography still present some drawbacks. Firstly,
it is an ionizing technique, and although the radiation dose has
considerably decreased, it is still relevant if we take into account
that the breast is a radiosensitive tissue. Secondly, mammogra-
phy cannot differentiate between liquid lesions, including cysts,
and solid lesions, which is a major limitation for the accurate
identification of tumor masses.
Two innovative techniques are included within
mammography:
Contrast-enhanced mammography
Contrast mammography, as well as MRI, allows dynamic vascu-
lar studies to be performed. Several parameters can be extracted
from the enhancement curve that provide useful diagnostic infor-
mation, such as the slope and the time to peak. Thus, lesions
with early and intense enhancement are suggestive of malignancy
(Fallenberg et al., 2014).
This type of study has been satisfactorily used for the anal-
ysis of inconclusive lesions, the detection of occult lesions, the
monitoring of disease progression and to assess chemotherapy
response (Dromain et al., 2009).
Tomosynthesis
Tomosynthesis techniques allow us to carry out three-
dimensional breast studies. It consists of a mammography
device that uses a rotary head tube, performing different projec-
tions of a static breast with a specified angle (between 15◦ and
45◦). It can be considered a tomographic application of digital
mammography. Tomosynthesis has even been proposed as a new
screening method (Waldherr et al., 2013). Tomosynthesis has
demonstrated superior accuracy compared to mammography in
tumor measurements and reduced the suspicious presentations
of normal tissues and tissue overlap, and facilitated accurate
differentiation of lesion types (Fornvik et al., 2010; Alakhras
et al., 2013).
ULTRASOUND
Ultrasound complements mammography, being a required
method for the management and diagnosis of breast pathology
(Figure 2). Because it does not use ionizing radiation, ultrasound
is not only the first diagnostic tool in young women who have lit-
tle risk of breast cancer, but also the first diagnostic technique in
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FIGURE 2 | Breast cancer ultrasound images.
pregnant and breastfeeding women. Moreover, it has high sensi-
tivity to show tumor margins and the internal characteristics of
tissue, and it is used as complementary technique to mammog-
raphy for the study of dense breasts and to assess lymph node
status. It is also frequently used for breast intervention, for guided
biopsy and for the placement of harpoons. In recent years, differ-
ent ultrasound techniques for the breast pathology studies have
been developed, including:
Ultrasound contrast
Ultrasound contrast involves the intravenous injection of per-
fluorocarbon microbubbles to observe the behavior of breast
lesions by ultrasound. The perfusion area and the signal inten-
sity curves in relation to time are obtained using this method.
Ultrasound contrast is used for diagnosis, detection of recurrence
and monitoring of treatment response, and is particularly useful
as a guide for puncture of suspicious lymph nodes, as metastatic
lymph node areas do not capture contrast and can be therefore
differentiated from healthy areas.
On the other hand, 3D ultrasound is particularly useful for
the study of breast lesion with contrast, because it allows the
assessment of nodes with contrast in three dimensions (Jia et al.,
2014).
Elastography
This technique is based on the same principle as breast tender-
ness and can determine the hardness of the lesion by measuring
the elastic properties of tissues by ultrasound, as the lower the
hardness of a lesion, the higher the probability of being benign,
and vice versa. Elastography has been shown to be very useful in
the assessment of benign lesions (BIRADS 3) (Itoh et al., 2006;
Scaperrotta et al., 2008).
MAGNETIC RESONANCE IMAGING (MRI)
MRI is an important diagnostic tool frequently used to study
breast disease. It currently has specific indications, including eval-
uation of response to treatment, screening in high-risk patients,
study of occult breast cancer, study of tumor recurrence and
assessment of breast prostheses. MRI can be also recommended
for the staging of breast cancer, the study of microcalcifica-
tions, breast discharge, premalignant lesions, residual tumor in
operated patients or in case of inconclusive findings by mam-
mography and ultrasound (Mann et al., 2008; Sardanelli et al.,
2010).
The MRI techniques applied to the study of breast cancer are
based on both the assessment of the morphological features of
the lesions and the characteristics of contrast enhancement of
these lesions. Malignant tumors have a disorganized angiogenesis
showing specific morphological and functional characteristics.
The MRI study includes pre-contrast T2 sequences and post-
contrast 3D T1-weighted gradient Eco. Several parameters are
analyzed in the contrast studies, such as the slope of the enhance-
ment curve during both the uptake and wash out phases, the
time to peak enhancement or the maximal relative enhancement.
These analyses can differentiate benign from malignant lesions.
Image post-processing plays an important role in dynamic con-
trast MRI because it provides the radiologist with additional
parametric information that can be crucial for a more accu-
rate diagnosis. Thus, typical post-processing processes include
subtraction of images, projections of maximum signal intensity
(MIP), multiplanar reconstructions (MPR) and time curves of
suspicious lesions uptake (Kuhl, 2007; Partridge, 2008).
Currently, there are two classification systems for the diag-
nostic criteria in breast MRI: the Fischer and the ACR classi-
fications. Both present common diagnostic criteria, integrating
morphological and dynamic uptake information. The ACR classi-
fication presents common criteria with the BIRADS classification
ofmammography and ultrasound (Agrawal et al., 2009;Morris Ea
et al., 2013). During the last few years, other MR techniques have
been proposed for the study of breast cancer, namely diffusion
MRI and spectroscopy.
Diffusion MRI
Diffusion MRI techniques are based on the application of field
gradients to enhance the signal lost due to the Brownian motion
of water molecules. The diffusion weighting is determined by the
strength and duration of the diffusion gradients, and the time
between the gradient pulses, which is all quantified by the b-
factor. The exponential fit of signal intensity vs. the b values
provides the apparent diffusion coefficient (ADC), whose val-
ues reflect the restriction of water motion in any given tissue
and, in the case of tumor growth, it has been related to cellular-
ity. Malignant tumors usually have high cellularity and therefore
present low ADC values as compared to benign lesions. Diffusion
MRI is a quick technique that does not require the use of contrast
agents and its implementation has been recommended as part of a
routine protocol for breast MRI. Themain disadvantages of diffu-
sion MRI are the low spatial resolution and the lack of specificity
to differentiate between benign andmalignant tumors (Guo et al.,
2002; Peters et al., 2008).
MR spectroscopy
Breast spectroscopy provides information about the metabolic
profile of tumor tissue, being the most important metabolite in
breast spectroscopy tCho (total choline), which has been related
to tumor proliferation activity. The use of spectroscopy has been
shown to increase the specificity of MR for the differentiation of
benign andmalignant lesions. Several studies indicate the associa-
tion between the choline peak with the response to the treatment.
In this sense, Tozaki et al. (2010) found that the reduction of
choline peak is more sensitive to determining the response to
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treatment than the decrease of tumor size. Furthermore, the com-
bination of spectroscopy and diffusion MRI data have demon-
strated a high specificity to characterize benign and malignant
lesions (Tsougos et al., 2014).
CONTRAST AGENTS
In spite of the multiple image diagnostic tools commented on
above, radiologists still find some difficulties when diagnosing
early stage breast tumormalignancies due to the lack of sensibility
given for these techniques. Early detection has become one of the
most important issues in the cancer treatment, and researchers
have improved this issue by developing external substances called
contrast agents that enhance the sensibility of images in the region
of interest. This fact allows improvement to the quality and the
follow-up of molecular processes at the cellular and molecular
levels of the region under study. The more common contrast
agents used in clinical studies are gadolinium- and iodine-based
structures for magnetic resonance imaging and mammography
(X-ray) respectively, however other contrast agents such as radio-
tracers are being investigated as potential biomarkers for daily
clinical practice.
MAGNETIC RESONANCE IMAGING CONTRAST AGENTS
As noted above, the gadolinium-based contrast agents are the
most commonly used in clinical practice, generating a positive
image of the nearby tissues. The presence of gadolinium ions
shortens the T1 relaxation time, thus generating an increase of
the intensity in the images (bright signal or positive image) that
help to distinguish malignancies from other benign pathologies
(Zhou and Lu, 2013). However, gadolinium is a high toxic para-
magnetic cation (Gd3+) that needs to be protected from the body,
so gadolinium is mainly reacted with chelate ligands thus min-
imizing the toxicity effects from the free gadolinium (Gd3+).
Therefore, the most typically used gadolinium chelates as MRI
contrast agents in clinical practice are gadopentetate dimeglu-
mine (Gd-DTPA, Magnevist®), gadoterate dimeglumine (Gd-
DOTA, Dotarem®), gadoteridol (Gd(HP-DO3A), Prohance®),
and gadodiamine (Gd(DTPA-BMA), Omniscan®). These con-
trast agents, approved by the Food and Drug Administration
(FDA), present excellent biodistribution within the extracellular
space, and fast renal clearance from the body with half-lives of
1–2 h. Albeit the most used gadolinium-based contrast agents are
the Gd-chelates, complex gadolinium-based contrast agents have
been developed to improve their T1 relaxation time and phar-
macokinetics. These complexes provide well-defined advantages
over Gd-chelates due to slow rotational motion, they are a com-
bination of Gd-chelates, such as Gd-DTPA and Gd-DOTA, and
dendrimers (Li et al., 2013) or liposomes (Huang and Tsourkas,
2013; Zhou and Lu, 2013). For instance, poly(amidoamine)
PAMAM dendrimers in different generations have shown higher
r1 relaxivity and size-dependent pharmacokinetics, low genera-
tion (2–4) presented renal clearance, and high generation (5–10)
presented minimal renal clearance. A recent modification in the
design of contrast agent dendrimers resulted in the development
of dendrimer nanoclusters (DNCs), as a combination of small
PAMAMdendrimers. These DNCs were easily synthesized in high
yields and also exhibited higher r1 values than the small units of
PAMAM-based contrast agents (Cheng et al., 2010). These Gd-
chelates were also combined with liposomes via encapsulation in
the inner core or immobilization at the liposome surface, being
the immobilization most used since the relaxivity is higher than
in the encapsulated method, thus exhibiting a low water exchange
rate with the gadolinium encapsulated in the inner core of the
liposome.
X-RAY CONTRAST AGENTS
Iodine-based contrast agents improve the visualization of images
in radiography and CT by increasing the density of tissues and
also the vessels. Similarly to dynamic MRI using Gd chelates,
relevant information can be extracted from the different uptake
kinetics of these contrast agents that helps in differentiating
malignant lesions from benign tissues. In case of malignant tis-
sues, the iodine is rapidly absorbed and desorbed (more contrast),
while in the benign ones the absorption takes place slowly (less
contrast), thus giving differences in the tissue density of the
images. Iodine contrast agents could be sorted into two groups
depending on the binding to the iodine: covalent (non-ionic)
or ionic contrast agents (Robbins and Pozniak, 2010). The ionic
contrast agents present are better contrast agents than the non-
ionic ones due to their higher osmolality, with the consequently
increased delivery or disassociation of iodine (Barrett et al., 1992).
However, the ionic iodine contrast agents induces more toxicity
(more side effects) mainly due to the large amount of iodine ions
delivered (higher osmolality injected in comparison with serum),
being also recently reported that these contrast agents could affect
the thyroid in some patients (Rhee et al., 2012). Therefore, in
order to minimize the toxicity, the contrast agents used for the
clinical practice present values close to the serum, and non-
ionic bonds such as Iohexol 300mg Iodine/mL (Omnipaque) and
Iodixanol 320mg Iodine/mL (Visipaque).
POSITRON EMISSION MAMMOGRAPHY (PEM)
PEM is high-resolution PET scanner that provides functional
imaging specifically for breast cancer detection (Kalles et al.,
2013). PEM can isolate and enhance breast images with more
accuracy than full-body PET scans and works much like a full-
body PET scan (see Section PET and SPECT). In this tech-
nique, the contrast agents used in the evaluation of breast cancer
are radiotracers (Penuelas et al., 2012), in particular radioac-
tive labeled sugar-like molecules. These radiotracers help the
diagnostic accuracy of the cancer, especially in the early stages,
metastasis, and also cancer progression during the treatment. 18F-
fluorodeoxiglucose (FDG) (Caldarella et al., 2014) is the most
typical radiotracer used as a contrast agent in PEM. FDG is an
analog of glucose that is accumulated, after injection, mostly in
cancer tissues, since those present a faster metabolism in com-
parison with the normal tissues allowing a more clear vision of
the suspected malignant tissues by PEM. Another radiotracer is
the 3′-deoxy-3′-[18F]fluorothymidine (18FLT). This radiotracer is
not still used as a routine breast cancer contrast agent in clinical
practice, but it has been tested as a biomarker for imaging cellu-
lar proliferation. 18FLT is a structural analog of DNA nucleoside
thymidine that is trapped in the cell thus informing about the
stage or monitoring the evolution of the tumor cells (Caldarella
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et al., 2014). In addition to the imaging of breast cancer prolifera-
tion and progression, the N-[11C]methylcholine (11C-choline) is
used as a radiotracer (Contractor et al., 2009) since the choline
is modified to phosphocholine due to the increase of the activ-
ity of the enzyme choline kinase-α as noted above in the MR
spectroscopy section.
MOLECULAR IMAGING TECHNIQUES FOR BREAST CANCER
The term “molecular imaging” refers to the non-invasive visual-
ization and measurement of biological processes at the cellular
and molecular levels in a living system using endogenous or
exogenous markers.
There are many different imaging modalities that can be used
for molecular imaging, the most relevant ones being: nuclear
imaging (PET and SPECT), optical imaging and magnetic reso-
nance imaging.
The direct observation of endogenousmarkers can be achieved
with magnetic resonance in vivo spectroscopic imaging (MRSI)
(Begley et al., 2012; Bolan, 2013) or some advanced optical
methods, such as Raman spectroscopy (Kallaway et al., 2013).
The first one is based on classical nuclear magnetic resonance
(NMR) spectroscopy, which allows the detection and quantifi-
cation of molecules containing magnetic nuclei, typically 13C,
31P, 19F or 1H, being 1H NMR the most widely used in vivo.
The combination of NMR sequences with field gradients in MRI
scanners allows for the spatial localization of the observable
metabolites, giving rise to MRSI. Both 1H and 31P MRSI have
been used for the metabolic characterization of breast tumors
at a high magnetic field (Klomp et al., 2011). Raman spec-
troscopy is based on inelastic scattering of photons after inter-
action with vibrating molecules and thus provides information
about tissue composition (Brozek-Pluska et al., 2012; Li et al.,
2014).
The term molecular imaging, however, most commonly refers
to the use of exogenous markers (contrast agents) to visualize and
measure in vivo processes. For breast cancer diagnosis, PET and
SPECT have been widely used in clinical practice, whereas MRI is
expected to have a major impact in the near future, and optical
imaging is mainly used in preclinical studies.
PET AND SPECT
PET imaging uses radioactive isotopes that emit positrons, such as
18F, 15O, 13N, or 11C; whereas SPECT imaging uses isotopes that
emit gamma photons, such as 99mTc, 123I, or 125I. Positrons travel
short distances in tissues, in the order of millimeters, and col-
lide with surrounding electrons (annihilation), producing two
high energy gamma rays that travel in opposite directions to one
another and are detected by the PET camera. The time delay
between the detection of paired opposite direction is used to cal-
culate the location of the annihilation event. In SPECT, a single
photon is emitted per event and detected by rotating gamma
cameras.
Most PET radioisotopes are short-lived, ranging from a few
minutes to 2 h, which implies the availability of an on-site
cyclotron to produce them and therefore increases the cost of
PET imaging dramatically. SPECT radioisotopes are longer-lived,
in the order of hours (6 h for 99mTc), allowing for longer image
acquisition times. On the other hand, PET shows higher sensitiv-
ity as compared to SPECT.
Both PET and SPECT provide information about physiological
activity, such as glucose metabolism, blood flow and perfusion,
and oxygen utilization (Kjaer, 2006). However, they lack anatom-
ical detail, which has led to the development of hybrid systems
that combine PET and SPECT with other image modalities, CT
and MRI.
Both whole-body and dedicated PET/CT scanners are cur-
rently available. Dedicated systems have higher sensitivity allow-
ing for the detection of small tumors and thus being more
accurate for molecular imaging, whereas whole-body scanners
provide valuable information for locoregional and distant staging
(Koolen et al., 2012). PET/MRI is a more recent technology that
offers the advantage of lower exposure to radiation and higher
contrast resolution, together with the possibility of adding func-
tional information from other MRI modalities, which has great
potential for molecular imaging. However, further technological
developments are still needed to get optimal performance of a
fully integrated PET/MRI system (Pace et al., 2014). SPECT/CT
has shown to be a valuable tool for sentinel lymph node detection
(Husarik and Steinert, 2007; Lerman et al., 2007; Van Der Ploeg
et al., 2009; Coffey and Hill, 2010).
OPTICAL IMAGING
Optical molecular imaging of the breast is based on the use of
near-infrared (NIR) light to excite exogenous fluorescent probes
that have been designed to selectively target breast tumor cells
(Levi et al., 2007; Poellinger, 2012). The use of NIR-fluorophores
for immunohistochemical characterization of excised tumor
specimens is a common in vitro diagnostic technique. The goal
of molecular imaging, however, is to detect these fluorophores
in vivo, thus avoiding the need for biopsies. There are technical
limitations, though, that need to be addressed if these methods
are to be used on patients, like tissue penetration and back-
ground signal contamination. To date, the use of NIR optical
imaging in vivo is limited to tumor xenografts in preclinical stud-
ies (Oliveira et al., 2012; Sano et al., 2012; Van De Ven et al., 2012)
or intraoperative imaging for tumor margin detection and lymph
node mapping (Lee et al., 2010; Verbeek et al., 2014).
MOLECULAR MAGNETIC RESONANCE IMAGING
MRI has attracted a great deal of interest in the era of molecular
imaging, as it is the most versatile diagnostic imaging modality,
able to provide excellent anatomical detail, together with func-
tional and metabolic information (Figure 3). Furthermore, its
non-ionizing nature offers the possibility of performing longitu-
dinal follow-up studies without any risk for the patient.
The majority of the MRI signal comes from the water pro-
tons (1H) and the contrast from the local differences in water
content, water motion and magnetic relaxation times, T1 and
T2, of the water protons. Although intrinsic contrast is suffi-
cient for most MRI applications, the use of exogenous contrast
agents is often required for accurate diagnosis. MostMRI contrast
agents are based on either gadolinium chelates or superparamag-
netic nanoparticles (SPIONs), these being the base for molecular
imaging.
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FIGURE 3 | Breast MRI images at 1.5T. A conventional breast MRI image
(without contrast agent) (A). A breast prosthesis can be seen in the right
breast (B).
In contrast to nuclear and optical imaging modalities, which
are based on the direct detection of molecular probes, molec-
ular magnetic resonance imaging is an indirect method that
detects the effect of the contrast agents on the magnetic proper-
ties of the surrounding water molecules. This is a crucial aspect
in understanding MRI-based molecular imaging, as explained
below.
The major drawbacks of MRI for molecular imaging appli-
cations are, on the one hand, its inherent low sensitivity, due
to the small difference in atoms between the high and the low
energy states, and on the other hand, the lack of specificity of con-
ventional MRI contrast agents. Thus, molecular imaging probes
have to be able to strongly increase sensitivity and at the same
time show high specificity. In this regard, SPIONs (Lodhia et al.,
2010; Ittrich et al., 2013; Jin et al., 2014) have important advan-
tages over other magnetic contrast agents because they produce
signal enhancement through local field inhomogeneities, which
affects the T2 of a large number of water molecules, thus leading
to very strong signal enhancement. Nonetheless, other types of
contrast agents have also been proposed for magnetic resonance
molecular imaging, such as Gd-based nanoparticles (Huang and
Tsourkas, 2013). Finally, the functionalization of these nanosys-
tems using technological approaches adds both specificity and
biocompatibility.
Some studies have already shown the great potential of mag-
netic resonance for molecular imaging of breast cancer using
targeted nanoparticles (Li et al., 2013; Yan et al., 2013). Although
these studies have been only conducted in animal models, it can
be expected that, in the near future, the rapidly growing field of
nanomedicine will facilitate the translation of these methodolo-
gies to the clinics.
PERSPECTIVES
Although molecular imaging is able to visualize breast tumor
morphology and functional and metabolic processes within the
tumor at several levels, the sensitivity of the different molecular
imaging techniques is varied depending on the type of marker
used in signaling the biological processes. At present, the main
milestones for future molecular imaging development in breast
cancer are:
1. To enhance knowledge of molecular drivers behind breast
cancer subtypes, progression and metastasis.
2. To develop validated markers for chemosensitivity and
radiosensitivity.
3. To validate multimodality imaging biomarkers for minimally
invasive diagnosis andmonitoring of responses in primary and
metastatic disease.
4. To develop interventions and support to improve the survivor-
ship experience.
In 2012, the charity Breast Cancer Campaign facilitated a series
of workshops where specialists and other stakeholders revealed
the main gaps in the prevention and treatment of breast can-
cer (Eccles et al., 2013). Top problems in molecular imag-
ing of breast cancer (and recent research on the field) to be
highlighted are:
1. There is a need to increase the use of functional screening
techniques to learn about tumor heterogeneity, identify fea-
tures associated with response or resistance to treatment and
accelerate the rate at which promising ones enter clinical eval-
uation. The “Europe Against Cancer” programme has created
quality assurance guidelines used for all mammography-based
screening for breast cancer. They were created to maximize
results while minimizing negative effects. The Mammography
Quality Standards Act (MQSA) in the United States has man-
dated that all mammography clinics be certified (Von Karsa
and Arrossi, 2013). Resistance to chemotherapy has brought to
light the issue of tumor heterogeneity. Approximately 70% of
human breast tumors are ER positive and depend on estrogen
for growth. The use of selective ERmodulators, such as tamox-
ifen, in ER-expressing tumors was one of the first examples
for successful targeted therapy based on the tumor’s molecu-
lar classification (Swaby et al., 2007). What induces endocrine
resistance in these tumors has been one of the longest standing
and most intense areas of breast cancer research. The somatic
evolution of tumor progression was discovered in 2012, but the
results raised additional questions that could not be answered
at that time (Greaves and Maley, 2012). One of the most excit-
ing outcomes of comprehensive cancer-genome-sequencing
studies is that we finally have the tools to follow clonal and sub-
clonal evolution of tumors and see the complexity of cancers
as a whole (Polyak, 2014).
2. Evaluation of emerging imaging biomarkers of primary and
metastatic breast cancer. A biomarker is a crucial tool for
measuring the progress of disease and the effects of treat-
ment for better clinical outcomes in breast cancer patients.
The current questions of therapeutic choices can focus now
on the understanding that breast cancer is truly a collection
of genetically-specific heterogeneous diseases, each demon-
strating different clinical behavior and therapeutic response
(DeMattos-Arruda et al., 2013). Several biomarkers have been
proposed as new breast cancer targets, including MicroRNAs
(mi-RNA) (Mulrane et al., 2014), proteins (Kondo, 2014),
antibodies (Knowles and Wu, 2012), or glycans (Adamczyk
et al., 2012). One promising direction is the detection and
imaging of circulating cell-free DNA (cf-DNA). Since 2002,
cf-DNA has been shown to represent a good non-invasive
biomarker, as it can be isolated from human plasma, serum
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and other body fluids (Utting et al., 2002). It was also
reported that the concentration of DNA in the bloodstream
of patients with breast cancer was higher than healthy con-
trols (Fleischhacker and Schmidt, 2007). Thus, the detection
of cf-DNA provides new opportunities for management of
cancer patients, adding a useful new tool for diagnosis, stag-
ing and prognosis (Esposito et al., 2014). Imaging of cf-DNA
after chemotherapy treatment has been described by using
fluorochrome-functionalized nanoparticles (Cho et al., 2013).
Very recently, cf-DNA from plasma samples has been imaged
by AFM and allowed to confirm the specific size pattern of
tumor-derived cf-DNA (Mouliere et al., 2014).
3. Increased specificity and improved clinical translation of
radiotracers for positron emission tomography/single-photon
emission computed tomography (PET/SPECT). Since the dis-
covery of GLUT family proteins overexpression associated
with certain tumors, a variety of radiolabeled glucose deriva-
tives have been developed as SPECT and PET tumor imaging
agents. [18F]FDG is by far the most widely used in PET
imaging for cancer diagnosis. Unfortunately, clinical usage is
limited due to the need for the presence of cyclotron in 18F
production. Generator produced isotopes, such as 99mTc and
68Ga, are readily available and affordable. The availability of a
generator and kit chemistry to prepare 99mTc and 68Ga-based
molecular probes may have a significant impact on nuclear
medicine (Liu et al., 2014). It has been shown that 99mTc-
glucarate may behave as a suitable alternative to 18F-FDG as a
promising breast tumor imaging agent and needs to be further
investigated (Gambini et al., 2011). Thus, using generator-
produced isotopes to label glucose analogs is the major focus
of ongoing research.
4. Identification and assessment of using imaging biomarkers
currently associated with other cancer indicators in addi-
tional hallmarks such as hypoxia, invasion and changes in
metabolism. During the past decades, researchers have tried to
elucidate the mechanisms that underlie cancer-related death.
However, this remains a challenge, as genomic instability
causes a constantly changing genetic profile of tumors, and
local variations in the microenvironment cause heterogeneity
in tumor cell behavior (Polyak, 2014).
5. How to validate novel imaging biomarkers in adequately
powered multi-center clinical trials. While applied molec-
ular biology to cancer has made great advancements, the
development of clinically validated biomarkers for primary
breast cancer has remained an unconquerable task. Chemo-N0
(1993–1998) was the first prospective randomized multicenter
trial in Node-negative breast cancer designed to prospectively
evaluate the clinical utility of a biomarker. Its results estab-
lished uPA/PAI-1 as a clinically useful biomarker for assessing
long-term prognosis in early breast cancer and benefit from
adjuvant chemotherapy in the high-risk group; it is thus well-
suited for routine risk assessment in node-negative breast can-
cer (Harbeck et al., 2013). The Node Negative Breast Cancer
Trial (NNBC), initiated by the Swedish Breast Cancer Group,
was able to validate a prognostic index consisting of a pro-
liferation factor, PR-status, and tumor size. The index may
be helpful for prognostic considerations and for selection of
patients in need of adjuvant therapy (Klintman et al., 2013).
Although still in their infancy, circulating mi-RNAs and cf-
DNA are beginning to be recognized as vital to future strate-
gies on therapies for breast cancer (Ng et al., 2013; Esposito
et al., 2014). mi-RNAs have become the rising stars for novel
molecular targeting treatments because of their ability to regu-
late multiple genes inmolecular pathways (Si et al., 2013). Very
recently, a Phase 1 clinical study of MRX34, the first miRNA
to advance into a human clinical trial for liver cancer, was
approved (Mirna Therapeutics, 2014).
6. Methods of reporting intratumoral heterogeneity and locate
the most beneficial areas for biopsies and radiotherapy. Within
the plethora of imaging modalities, diffusion weighted mag-
netic resonance imaging (DW-MRI) has shown promise for
the detection and characterization of breast cancer. Apparent
diffusion coefficient (ADC) values allow quantification of the
diffusion signal, and can facilitate in differentiating benign and
malignant breast tumors as well as identifying early response
in tumors undergoing preoperative treatment (Partridge and
McDonald, 2013 and the references cited therein). On the
other hand, the heterogeneous nature of cancer still presents
an important challenge in cancer imaging and therapeutics
(Seoane and De Mattos-Arruda, 2014). This heterogeneity
also confers to the different breast cancer subtypes a spe-
cific invasional kinetic pattern, as has been recently shown by
Yamaguchi et al. using MRI studies (Yamaguchi et al., 2014).
Although breast MRI accuracy for assessing residual disease
is good and surpasses other diagnostic techniques, overes-
timation and underestimation of residual disease have also
been observed. This is largely because of the various treatment
types and breast cancer subtypes (Lobbes et al., 2013). With
some limitations and taking into consideration that many
of the experiments have been performed in mice, intravi-
tal microscopy (IVM) is another technique that has proven
its power to elucidate the cellular and molecular events that
underlie the hallmarks of cancer. Fluorescence-guided surgi-
cal procedures have also benefited from IVM, which translates
into more promising uses in the clinical setting (Ellenbroek
and Van Rheenen, 2014).
7. Extension of methods that identify and define subtypes of
cancerous tumors —DCIS, TNBC and luminal types—with
non-invasive procedures (which may identify mixed lesions
missed by homogenized or limited sample analyses) and assess
heterogeneity between metastases. In recent years, there has
been an explosion in the field of nanomedicine with the devel-
opment of new nanoparticles for the diagnosis and treatment
of cancer, and the related term “nanooncology” has been
adopted by many (Thakor and Gambhir, 2013). The devel-
opment of new contrast agents for MRI opens a new way
for non-invasive breast cancer characterization. Special atten-
tion is made to iron oxide nanoparticles, currently one of the
best options in clinic due to its lack of toxicity (Kievit and
Zhang, 2011; Rosen et al., 2012). Meier et al. used magnetic
nanoparticles (SPIONs) decorated with folic acid to image FR-
positive human breast cancer cell lines non-invasively (Meier
et al., 2010). Very recently, Sun et al. have developed SPIONs
functionalized with extra domain-B of fibronectin (EDB-FN)
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peptide for in vivo imaging of breast tumor initiating cells
(BTICs) by MRI (Sun et al., 2014). The development of new
algorithms in contrast enhanced MRI is also enabling good
discrimination of triple-negative cancers from non–triple-
negative cancers, as well as between triple-negative cancers
and benign fibroadenomas (Agner et al., 2014). This computer
assisted diagnosis opens a new window for quick breast cancer
identification and therapeutical match.
8. Combination of multidisciplinary inter-field data. It has been
recommended that imaging studies (both preclinical and clin-
ical) would need to be coregistered with linked genomic and
proteomic information in order to fully understand the bio-
logical implications of the images registered (Segal et al.,
2007; Lambin et al., 2012; Waterton and Pylkkanen, 2012).
Currently, imaging studies are often separated from tissue col-
lection due to a lack of appreciation of how the coordination
could benefit.
9. Identification and evaluation of biomarkers with therapeutic
responses. More extensive usage of orthotopic xenograft and
transgenic murine models of primary and metastatic breast
cancer will demand robust preclinical imaging approaches.
Trials that make use of these images will experience increased
accuracy for novel agents, which in turn can speed up the
development of successful treatments and the early cessation
of those that show no promise (publication of negative results
has been recommended by many researchers Alcantara et al.,
2010; Anderson et al., 2013). These preclinical trials might also
lead to sequential and combination treatment regimens.
As has been listed above, there are many new and emerging
molecular imaging technologies that can benefit breast cancer
patients. Other molecular imaging procedures under develop-
ment often combine imaging systems to form hybrid technologies
that improve accuracy and allow physicians to see how cancermay
be affecting other systems in the body. One of the more promis-
ing research areas is in investigational PET imaging biomarkers,
such as fluorothymidine (FLT) and fluoroestrogen (FES). FLT has
shown promise for the demonstration of tumor proliferation and
FES for the demonstration of estrogen receptors. Other exciting
area of study is radioimmunotherapy, a form of treatment that
targets cancer-killing radiation directly to cancer cells (out of the
scope of this review).
CONCLUSIONS
The past 40 years have seen stunning improvements in the ability
of noninvasive imaging to characterize structures and functions.
These strides have come from the progressive evolution of con-
ventional imaging techniques, with relatively little impact from
imaging targeted to specific molecular moieties. Although the
basic science of molecular imaging continues to make impres-
sive strides, the regulatory and commercial landscape is limiting
to these investigational imaging agents.
We anticipate that future needs will include the develop-
ment of nanomaterials that are specific for immune cell subsets
and can be used as imaging surrogates for nanotherapeutics.
New in vivo imaging clinical tools for noninvasive macrophage
quantification are thus ultimately expected to become relevant to
predicting patients’ clinical outcome, defining treatment options
and monitoring responses to therapy.
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